lubiprostone IBS-C
Selected indexed studies
- Recent advances in the treatment of irritable bowel syndrome. (Pol Arch Intern Med, 2021) [PMID:34463082]
- AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. (Gastroenterology, 2022) [PMID:35738724]
- Linaclotide: promising IBS-C efficacy in an era of provisional study endpoints. (Am J Gastroenterol, 2012) [PMID:23160292]
_Worker-drafted node — pending editorial review._
Connections
lubiprostone IBS-C is a side effect of
Sources
- Recent advances in the treatment of irritable bowel syndrome. (2021) pubmed
- Lubiprostone: RU 0211, SPI 0211. (2005) pubmed
- Lubiprostone: in constipation-predominant irritable bowel syndrome. (2009) pubmed
- Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. (2009) pubmed
- Linaclotide: promising IBS-C efficacy in an era of provisional study endpoints. (2012) pubmed
- AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. (2022) pubmed
- Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders. (2017) pubmed
- Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. (2011) pubmed
- Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. (2021) pubmed
- Lubiprostone for the treatment of adult women with irritable bowel syndrome with constipation. (2012) pubmed